OKYO Pharma (NASDAQ:OKYO) stock jumped 14% Wednesday after announcing encouraging Phase 2 clinical trial results for urcosimod, their investigational drug aimed at neuropathic corneal pain (NCP). The ...

The Andhra Pradesh State Council of Higher Education (APSCHE) has released the AP ECET 2025 Phase 2 counselling schedule.

After 12 weeks of treatment, 75% of per-protocol patients receiving 0.05% urcosimod showed greater than 80% reduction in ...

It’ll be the 5th and 6th ones they’ve built so far. This partnership has been in the making since 2022, and Bright Community Trust broke ground on their first houses here in Gainesville in 2024. The ...

The molecule, developed in collaboration with Massachusetts-based Kailera Therapeutics, is headed for a new drug application ...

After the Grenfell fire there are many lessons to be learned. Architects and manufacturers should be able to demonstrate they ...

BI 1815368, a potential oral treatment to improve vision in patients with diabetic macular edema, is being investigated in a ...

Amirco Properties, a real estate company, is expected to break ground on the 4-acre, multi-building development—dubbed ...

Thunderbolts* introduced one of the MCU's most powerful heroes, but a new theory suggests his abilities are connected to an age-old villain.

Kairos Pharma, Ltd. (NYSE American:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces positive safety results from its ongoing Phase 2 ...

Rhythm Pharmaceuticals’ push to move obesity patients from jabs to tabs has stayed on beat. | Rhythm Pharmaceuticals’ push to ...

The AP ECET 2025 counselling schedule for phase 2 has been issued. This will be the final round of admissions to the second year of Bachelor of Engineering (BE), Bachelor of Technology (BTech), and ...